trial

Pediatric Schizophrenia Efficacy and Safety Study

NCTId NCT01911429
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 327 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
327 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-08
Primary completion
2015-12
Eligibility
ALL · 13 Years · 17 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Investigators

1
Lurasidone Medical Director, MDStudy Director

Sites

90 total
Dothan, United StatesAnaheim, United StatesBakersfield, United StatesCulver City, United StatesDowney, United StatesGarden Grove, United StatesIrvine, United StatesOrange, United StatesPanorama City, United StatesRiverside, United StatesHartford, United StatesWashington D.C., United States

Linked catalysts

1
Pediatric Schizophrenia Efficacy and Safety Study — primary completion2015-12

Facts & assertions

4 sourced
Enrollment
327
Phase
PHASE3
Primary Completion Date
2015-12
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lurasidone Medical Director, MD
person